Aerpio Reports Second Quarter 2017 Financial Results

CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2017. Second Quarter 2017 Financial Highlights As of June 30, 2017, cash and cash equivalents totaled $29.8 million. Research and development expenses were $3.1 million for the second quarter of 2017, as compared to $2.9 million for the same period in 2016. Ge